Showing results (131-140 of 1,028) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|July 18, 2024
Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patientsSimon Feys, Agostinho Carvalho, Cornelius J Clancy, et al.
The Lancet. Respiratory Medicine|July 14, 2024
Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trialPaul Little, Jane Vennik, Kate Rumsby, et al.
The Lancet. Respiratory Medicine|June 8, 2024
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trialClaire Elizabeth Wainwright, Suzanna Vidmar, Vicki Anderson, et al.
The Lancet. Respiratory Medicine|June 17, 2024
Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancerEmmanouil Panagiotou, Ioannis A Vathiotis, Periklis Makrythanasis, et al.
The Lancet. Respiratory Medicine|July 11, 2024
Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic reviewSjanna B Besteman, Debby Bogaert, Louis Bont, et al.
The Lancet. Respiratory Medicine|August 17, 2023
Treatment of pulmonary arterial hypertension: recent progress and a look to the futureMarc Humbert, Olivier Sitbon, Christophe Guignabert, et al.
The Lancet. Respiratory Medicine|July 20, 2023
Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestationsMatteo Parotto, Mariann Gyöngyösi, Kathryn Howe, et al.
The Lancet. Respiratory Medicine|June 22, 2023
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trialSamuel M Brown, Christina E Barkauskas, Birgit Grund, et al.
The Lancet. Respiratory Medicine|January 29, 2019
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 studyJohn J McNamara, Susanna A McColley, Gautham Marigowda, et al.
The Lancet. Respiratory Medicine|September 24, 2020
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling studyYou Li, Emily K Johnson, Ting Shi, et al.
Pageof 103